Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.72 |
| ▸ | TPMT | P51580 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737305 | 0.84 | TTR (1.00) | TTRTPMTTSHRCA12CA1 | |
| SCHEMBL348297 | 0.84 | CA1 (0.56) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL2716447 | 0.83 | TTR (0.48) | TTRTSHRCA1CA2ALDH1A1 | |
| Bromide SCHEMBL28853691 | 0.82 | TTR (0.95) | TTRTPMTTSHRCA12CA1 | |
| SCHEMBL28766413 | 0.82 | CA1 (0.54) | TTRTPMTTSHRCA12CA1 | |
| SCHEMBL27690857 | 0.82 | CA1 (0.54) | TTRTPMTTSHRCA12CA1 | |
| SCHEMBL10300670 | 0.81 | TTR (0.56) | TTRTPMTTSHRCA12CA1 | |
| SCHEMBL27998994 | 0.80 | CA1 (0.52) | TTRTPMTTSHRCA12CA1 | |
| SCHEMBL401708 | 0.79 | KDM4E (0.55) | TTRTPMTCA12CA1CA2 | |
| SCHEMBL17732583 | 0.79 | TTR (0.44) | TTRALDH1A1HSD17B10KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014063199-A1 | ORGANIC COMPOUNDS | AKAAL PHARMA PTY LTD (AU) | 2014-05-01 | — | — | WO | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-7855192-B2 | Macrolactams by engineered biosynthesis | KOSAN BIOSCIENCES, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7491741-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080188450-A1 | A 2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-penntaen-9-ylcarbamate derivative; Heat shock protein 90 inhibitors; hyperproliferative disease, breast cancer, ovarian cancer, leukemia, colon cancer, lung cancer | KOSAN BIOSCIENCES INCORPORATED | 2008-08-07 | — | — | US | disclosed |
| US-20070155671-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER | 2007-07-05 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050080119-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2005-04-14 | — | — | US | disclosed |
| US-6803384-B2 | FOR THERAPY OF REPERFUSION INJURY | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040006236-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2004-01-08 | — | — | US | disclosed |
| US-6515124-B2 | (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis | HOFFMAN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1261579-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20020161237-A1 | Dehydroamino acids | HOFFMANN-LA ROCHE INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020052512-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2002-05-02 | — | — | US | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001058853-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | WO | disclosed |
| EP-1121342-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000021920-A1 | DIAMINOPROPIONIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161237-A1 | Dehydroamino acids | HSD3B1, CYP8B1, TH | TTR 2983/4885TPMT 33/4885TSHR 1248/4885 |
| US-20040006236-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | TTR 4613/4885TPMT 1819/4885TSHR 2834/4885 |
| US-20020052512-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | TTR 4613/4885TPMT 1819/4885TSHR 2834/4885 |
| US-20070155671-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | TTR 4578/4885TPMT 1782/4885TSHR 2665/4885 |
| US-20050080119-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | TTR 4578/4885TPMT 1782/4885TSHR 2665/4885 |
| US-20080188450-A1 | A 2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-penntaen-9-ylcarbamate derivative; Heat shock protein 90 inhibitors; hyperproliferative disease, breast cancer, ovarian cancer, leukemia, colon cancer, lung cancer | HSP90AB2P, HSP90AB1, HSPA1B | TTR 3969/4885TPMT 2612/4885TSHR 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.